Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

@article{Thiruppathi2014RecombinantIF,
  title={Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.},
  author={M. Thiruppathi and J. Sheng and Liangcheng Li and B. Prabhakar and M. Meriggioli},
  journal={Journal of autoimmunity},
  year={2014},
  volume={52},
  pages={
          64-73
        }
}
Myasthenia gravis (MG) is an autoimmune disorder caused by target-specific pathogenic antibodies directed toward postsynaptic neuromuscular junction (NMJ) proteins, most commonly the skeletal muscle nicotinic acetylcholine receptor (AChR). In MG, high-affinity anti-AChR Abs binding to the NMJ lead to loss of functional AChRs, culminating in neuromuscular transmission failure and myasthenic symptoms. Intravenous immune globulin (IVIg) has broad therapeutic application in the treatment of a range… Expand
37 Citations
Myasthenia gravis: the role of complement at the neuromuscular junction
  • J. Howard
  • Medicine
  • Annals of the New York Academy of Sciences
  • 2018
Targeting FcγRs to treat antibody-dependent autoimmunity.
Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease
A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity.
Myasthenia Gravis: paradox versus paradigm in autoimmunity.
New and emerging treatments of Guillain–Barré syndrome
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs
...
1
2
3
4
...

References

SHOWING 1-10 OF 83 REFERENCES
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice
Experimental Autoimmune Myasthenia Gravis in the Mouse
Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms
Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells.
Myasthenia gravis: past, present, and future.
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
...
1
2
3
4
5
...